The CEO of MicroStrategy just predicted that Bitcoin is ‘going up forever’ — here are 3 other companies with plenty of crypto on the balance sheet

TipRanks

Cassava: A Controversial Top Pick

This afternoon (Tuesday, Nov 9), the Clinical Trials on Alzheimer’s Disease (CTAD) conference will kick off in Boston. Cassava Sciences (SAVA) will be among those making presentations over the next few days with a poster titled, “Interim Results of an Open-label Study of Simufilam in Mild-to-Moderate Alzheimer’s Disease.” B. Riley analyst Mayank Mamtani expects the presentation to include a more rounded update of the topline 12-month cognition efficacy data released toward the end of Q3. Recall,